Literature DB >> 17312171

Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia.

Ziye Sui1, Lynn F Sniderhan, Giovanni Schifitto, Richard P Phipps, Harris A Gelbard, Stephen Dewhurst, Sanjay B Maggirwar.   

Abstract

HIV type 1 (HIV-1)-associated dementia (HAD) is believed to occur due to aberrant activation of monocyte-derived macrophages and brain-resident microglial cells by viral proteins as well as by the proinflammatory mediators released by infected cells. To investigate the inflammatory aspects of the disease, we examined the levels of soluble CD40L (sCD40L) in paired samples of plasma and cerebrospinal fluid obtained from 25 HIV-infected individuals. A significantly higher level of sCD40L was detected in both cerebrospinal fluid and plasma from HIV-infected patients with cognitive impairment, compared with their nonimpaired counterparts. The contribution of sCD40L to the pathogenesis of HAD was then examined by in vitro experiments. rCD40L synergized with HIV-1 Tat to increase TNF-alpha release from primary human monocytes and microglia, in an NF-kappaB-dependent manner. The mechanistic basis for this synergism was attributed to a Tat-mediated up-regulation of CD40 in monocytes and microglia. Finally, the CD40L-mediated increase in TNF-alpha production by monocytes was shown to be biologically important; immunodepletion experiments revealed that TNF-alpha was essential for the neurotoxic effects of conditioned medium recovered from Tat/CD40L-treated monocytes. Taken together, our results show that CD40 signaling in microglia and monocytes can synergize with the effects of Tat, further amplifying inflammatory processes within the CNS and influencing neuronal survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312171     DOI: 10.4049/jimmunol.178.5.3226

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Platelet decline as a predictor of brain injury in HIV infection.

Authors:  Ann B Ragin; Gypsyamber D'Souza; Sandra Reynolds; Eric Miller; Ned Sacktor; Ola A Selnes; Eileen Martin; Barbara R Visscher; James T Becker
Journal:  J Neurovirol       Date:  2011-09-29       Impact factor: 2.643

2.  Activation of Cannabinoid Type Two Receptors (CB2) Diminish Inflammatory Responses in Macrophages and Brain Endothelium.

Authors:  Yuri Persidsky; Shongshan Fan; Holly Dykstra; Nancy L Reichenbach; Slava Rom; Servio H Ramirez
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-11       Impact factor: 4.147

3.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

Review 4.  Childhood maltreatment and HIV-associated neurocognitive disorders share similar pathophysiology: a potential sensitisation mechanism?

Authors:  Jacqueline S Womersley; Soraya Seedat; Sian M J Hemmings
Journal:  Metab Brain Dis       Date:  2017-07-05       Impact factor: 3.584

5.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

6.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

Review 7.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.

Authors:  Michelle Kiebala; Oksana Polesskaya; Zhenqiang Yao; Seth W Perry; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

9.  Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway.

Authors:  Yong Zhang; Tao Huang; Yi Hu; Yu Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

10.  Vitamin D receptor deletion leads to reduced level of IkappaBalpha protein through protein translation, protein-protein interaction, and post-translational modification.

Authors:  Shaoping Wu; Yinglin Xia; Xingyin Liu; Jun Sun
Journal:  Int J Biochem Cell Biol       Date:  2009-11-30       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.